Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B Nov 19, 2025 09:45AM
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting Mar 5, 2024 04:45PM
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September Aug 29, 2023 08:30AM
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update Aug 3, 2023 08:00AM
Prelude Therapeutics To Participate in Jefferies Healthcare Conference May 31, 2023 08:30AM


May 8, 2023 08:30AM Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
Apr 27, 2023 08:30AM Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
Apr 27, 2023 08:30AM Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
Apr 11, 2023 08:30AM Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Mar 15, 2023 08:30AM Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 15, 2023 08:30AM Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
Mar 15, 2023 08:10AM Prelude Therapeutics (PRLD) Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
Mar 15, 2023 08:00AM Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
Mar 15, 2023 08:00AM Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
Mar 1, 2023 08:30AM Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
Mar 1, 2023 08:30AM Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
Feb 9, 2023 09:05AM Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Feb 9, 2023 09:05AM Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
Nov 14, 2022 08:00AM Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Nov 14, 2022 08:00AM Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Oct 18, 2022 08:00AM Prelude Therapeutics (PRLD) Granted FDA Clearance of IND for PRT3789
Oct 18, 2022 08:00AM Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Oct 18, 2022 08:00AM Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Sep 6, 2022 08:00AM Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
Sep 6, 2022 08:00AM Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
Aug 9, 2022 08:00AM Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update